These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8809086)

  • 1. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.
    Haining RL; Hunter AP; Veronese ME; Trager WF; Rettie AE
    Arch Biochem Biophys; 1996 Sep; 333(2):447-58. PubMed ID: 8809086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
    Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
    Haining RL; Jones JP; Henne KR; Fisher MB; Koop DR; Trager WF; Rettie AE
    Biochemistry; 1999 Mar; 38(11):3285-92. PubMed ID: 10079071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The substrate binding site of human liver cytochrome P450 2C9: an NMR study.
    Poli-Scaife S; Attias R; Dansette PM; Mansuy D
    Biochemistry; 1997 Oct; 36(42):12672-82. PubMed ID: 9335524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification and characterization of recombinant-expressed cytochrome P450 2C3 from Escherichia coli: 2C3 encodes the 6 beta-hydroxylase deficient form of P450 3b.
    Richardson TH; Hsu MH; Kronbach T; Barnes HJ; Chan G; Waterman MR; Kemper B; Johnson EF
    Arch Biochem Biophys; 1993 Jan; 300(1):510-6. PubMed ID: 8380971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function.
    Ridderström M; Masimirembwa C; Trump-Kallmeyer S; Ahlefelt M; Otter C; Andersson TB
    Biochem Biophys Res Commun; 2000 Apr; 270(3):983-7. PubMed ID: 10772937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9.
    Koenigs LL; Peter RM; Hunter AP; Haining RL; Rettie AE; Friedberg T; Pritchard MP; Shou M; Rushmore TH; Trager WF
    Biochemistry; 1999 Feb; 38(8):2312-9. PubMed ID: 10029524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydrophobic side chain requirements for lauric acid and progesterone hydroxylation at amino acid 113 in cytochrome P450 2C2, a potential determinant of substrate specificity.
    Straub P; Johnson EF; Kemper B
    Arch Biochem Biophys; 1993 Nov; 306(2):521-7. PubMed ID: 8215458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate probe for the mechanism of aromatic hydroxylation catalyzed by cytochrome P450.
    Darbyshire JF; Iyer KR; Grogan J; Korzekwa KR; Trager WF
    Drug Metab Dispos; 1996 Sep; 24(9):1038-45. PubMed ID: 8886617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe.
    Kaminsky LS; de Morais SM; Faletto MB; Dunbar DA; Goldstein JA
    Mol Pharmacol; 1993 Feb; 43(2):234-9. PubMed ID: 8429826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
    Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
    Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9.
    Mancy A; Dijols S; Poli S; Guengerich P; Mansuy D
    Biochemistry; 1996 Dec; 35(50):16205-12. PubMed ID: 8973193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
    Tracy TS; Hutzler JM; Haining RL; Rettie AE; Hummel MA; Dickmann LJ
    Drug Metab Dispos; 2002 Apr; 30(4):385-90. PubMed ID: 11901091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
    Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians.
    DeLozier TC; Lee SC; Coulter SJ; Goh BC; Goldstein JA
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1085-90. PubMed ID: 16099926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects.
    Maekawa K; Harakawa N; Sugiyama E; Tohkin M; Kim SR; Kaniwa N; Katori N; Hasegawa R; Yasuda K; Kamide K; Miyata T; Saito Y; Sawada J
    Drug Metab Dispos; 2009 Sep; 37(9):1895-903. PubMed ID: 19541829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.
    Kunze KL; Wienkers LC; Thummel KE; Trager WF
    Drug Metab Dispos; 1996 Apr; 24(4):414-21. PubMed ID: 8801056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase).
    Jones BC; Hawksworth G; Horne VA; Newlands A; Morsman J; Tute MS; Smith DA
    Drug Metab Dispos; 1996 Feb; 24(2):260-6. PubMed ID: 8742240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
    Thijssen HH; Flinois JP; Beaune PH
    Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.